Particularly, since the drug rivastigmine is a dual cholinesterase (AChE, BChE) inhibitor, a recognized key therapeutic target of AD (and also PD) [21], the development of rivastigmine hybrids appears to have remarkable advantages as potential anti-Alzheimer’s disease agents [22]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.